Ivacaftor

Drug Profile

Ivacaftor

Alternative Names: IVA; Kalydeco; Potentiator VX-770; VRT 813077; VX-770

Latest Information Update: 06 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics; Vertex Pharmaceuticals
  • Developer Vertex Pharmaceuticals
  • Class Amides; Aminophenols; Quinolones; Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cystic fibrosis
  • Phase II Chronic obstructive pulmonary disease

Most Recent Events

  • 01 Sep 2017 Vertex Pharmaceuticals completes a phase III trial in Cystic fibrosis (Combination therapy, In the elderly, In adolescents, In adults) in USA, Belgium, Canada, France, Greece, Ireland, Italy, United Kingdom, Australia, Austria and Germany (PO) (NCT02412111)
  • 16 Aug 2017 Vertex Pharmaceuticals initiates enrolment in a phase III trial for Cystic fibrosis (In neonates, In infants, In children) in USA, Australia and United Kingdom (NCT03277196)
  • 01 Aug 2017 Vertex Pharmaceuticals terminates a phase III trial in Cystic fibrosis (In children, Monotherapy) in Australia, Canada, and United Kingdom due to low enrolment (PO) (NCT02742519)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top